Abstract
The STARflo Glaucoma Device (iSTAR Medical, Wavre, Belgium) offers anew approach to bleb-free filtering surgery in which the intraocular pressure (IOP) is lowered by supporting outflow of the aqueous humor into the suprachoroidal space. On the basis of acase series of 9patients with open-angle glaucoma (OAG) unmanageable by drug-based treatment, intra- and postoperative experiences with the implant are presented. The implant, the implantation procedure, and the first results 6months postoperatively are described. No intraoperative complications were observed. Postoperative complications such as increased astigmatism or ocular hypotony were rare and transient. After 6months there was an IOP reduction from 29.1 mm Hg± 6.1 mm Hg with 2.7± 1.1 local IOP-lowering medications to 16.1± 4.1 mm Hg (IOP reduction of 44.7%) with additional 2.0± 0.8 local IOP-lowering medications. The new STARflo Glaucoma Device shows promising results in reducing the IOP of medically uncontrolled OAG. Further investigations concerning the long-time efficacy of the implant and additional IOP-lowering medication are still ongoing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
